ClinicalTrials.gg
CompletedNCT03391466ZUMA-7Updated Dec 1, 2025Results posted

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

A Phase 3 interventional study of Axicabtagene Ciloleucel and Platinum-containing Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Kite, A Gilead Company. Completed at 72 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Gilead Sciences.

Enrollment
Largest of 10
359 · median 63
Started
2018
the only one that year
Phase 3
2 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 3, and was the 11th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences as a file.
02

Study summary

The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Read the detailed description

After completing the treatment period, all participants will be followed in the post-treatment follow-up period for up to 5 years. Thereafter, participants who received at least one dose of axicabtagene ciloleucel as protocol therapy will transition to a separate long term follow up (LTFU) study and complete the remainder of the 15-year follow-up assessments within KT-US-982-5968 (NCT05041309).

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • proven large B-cell lymphoma (BCL) including the following types defined by World Health Organization (WHO) 2016.

    • Diffuse large B-cell lymphoma (DLBCL) not otherwise specified activated B-cell/ germinal center B-cell (ABC/GCB).
    • High-grade B-cell lymphoma (HGBL) with or without myelocytomatosis oncogene (MYC) and BCL 2 and/or BCL 6 rearrangement.
    • DLBCL arising from follicular lymphoma (FL).
    • T-cell/histiocyte rich large B-cell lymphoma.
    • DLBCL associated with chronic inflammation.
    • Primary cutaneous DLBCL, leg type.
    • Epstein-Barr virus (EBV) + DLBCL.
  • disease after chemoimmunotherapy.

    • Refractory disease defined as no complete remission to first-line therapy; individuals who are intolerant to first-line therapy are excluded.

      • Progressive disease (PD) as best response to first-line therapy.
      • Stable disease (SD) as best response after at least 4 cycles of first-line therapy (eg, 4 cycles of R-CHOP).
      • Partial response (PR) as best response after at least 6 cycles and -proven residual disease or disease progression ≤ 12 months of therapy.
    • Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven relapse ≤ 12 months of first-line therapy.
  • Individuals must have received adequate first-line therapy including at a minimum:

    • Anti-Cluster of Differentiation 20 antigen (CD20) monoclonal antibody unless investigator determines that tumor is CD20 negative, and
    • An anthracycline containing chemotherapy regimen.
  • No known history or suspicion of central nervous system involvement by lymphoma.
  • (ECOG) performance status of 0 or 1.
  • Adequate bone marrow function as evidenced by:

    • (ANC) ≥ 1000/μl
    • ≥ 75,000/μl
    • Absolute lymphocyte count ≥ 100/μl
  • Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

    • (Cockcroft Gault) ≥ 60 mL/min.
    • Serum /Aspartate aminotransferase (ALT/AST) ≤ 2.5 (ULN).
    • Total ≤ 1.5 mg/dl
    • Cardiac ≥ 50%, no evidence of pericardial effusion as determined by an Echocardiogram (ECHO), and no (ECG) findings.
    • No clinically significant pleural effusion.
    • Baseline oxygen saturation > 92% on room air.

Key Exclusion Criteria:

  • History of other than nonmelanoma skin cancer or carcinoma in situ (eg cervix, bladder, breast) unless disease free for at least 3 years.
  • Received more than one line of therapy for DLBCL.
  • History of or allogeneic stem cell transplant.
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management.
  • Known history of infection with (HIV) or (HBsAg positive) or anti- virus (HCV) positive. If there is a positive history of treated hepatitis B or hepatitis C, the viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
  • Individuals with detectable cerebrospinal fluid malignant cells or known , or with a history of cerebrospinal fluid malignant cells or brain metastases.
  • History or presence of non-malignant central nervous system (CNS) disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any disease with CNS involvement.
  • Presence of any indwelling line or drain. Dedicated central venous access catheter such as a Port-a-Cath or Hickman catheter are permitted.
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, Class II or greater congestive heart failure, or other clinically significant cardiac diseases within 12 months of enrollment.
  • History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
  • History of autoimmune disease, requiring systemic and/or systemic disease modifying agents within the last 2 years.
  • History of anti-Cluster of Differentiation 19 (CD19) or chimeric antigen receptor (CAR)-T therapy or history of prior randomization in ZUMA-7.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    Axicabtagene Ciloleucel Treatment

    Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation antigen (CD) 19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. Participants who will achieve a partial response or complete response and subsequently experience disease progression may have an option to receive a second course of conditioning chemotherapy and axicabtagene ciloleucel.

    Biological: Axicabtagene Ciloleucel · Drug: Cyclophosphamide · Drug: Fludarabine

  • Active comparator
    Standard of Care Therapy

    Participants will receive 2 or 3, 21-day cycles of second-line chemotherapy: * R-ICE:rituximab 375mg/m\^2 before chemotherapy, ifosfamide 5g/m\^2 24 hours continuous infusion (CI) on Day 2+mesna, carboplatin area under the curve (AUC)5 Day 2, maximum dose 800mg, etoposide 100mg/m\^2/day on Days 1-3; * R-ESHAP:rituximab 375mg/m\^2 Day 1, etoposide 40mg/m\^2/day IV on Days 1-4, methylprednisolone 500mg/day IV on Days 1-4 or 5, cisplatin at 25mg/m\^2/day CI Days 1-4, cytarabine 2g/m\^2 on Day 5; * R-GDP:rituximab 375mg/m\^2 Day 1 (or Day 8), gemcitabine 1g/m\^2 on Days 1 and 8, dexamethasone 40mg on Days 1-4, cisplatin 75mg/m\^2 Day 1 or carboplatin area under the curve (AUC)=5; or * R-DHAP:rituximab 375mg/m\^2 before chemotherapy, dexamethasone 40mg/day on Days 1-4, high dose cytarabine 2g/m\^2 every 12 hours for 2 doses on Day 2 following platinum, cisplatin 100mg/m\^2 24 hours CI on Day 1 or oxaliplatin 100mg/m\^2. Responders will receive high-dose therapy and autologous stem cell transplant.

    Drug: Platinum-containing Salvage Chemotherapy

Interventions

  • Administered intravenously

    Also known as: KTE-C19, axi-cel, Yescarta ®

  • DrugPlatinum-containing Salvage Chemotherapy

    Platinum-containing salvage chemotherapy (Rituximab-ifosfamide, carboplatin, etoposide (R-ICE), Rituximab-dexamethasone, cytarabine, cisplatin,oxaliplatin (R-DHAP), Rituximab-etoposide, methylprednisolone, cisplatin, cytarabine (R-ESHAP), or Rituximab-gemcitabine, dexamethasone, cisplatin/carboplatin (R-GDP) as selected by treating investigator).

  • Administered intravenously

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Event Free Survival (EFS) Per Blinded Central Assessment

    EFS:Time from randomization to disease progression (PD), best response of stable disease (SD) up to Day 150, start of new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD=Score 4 (uptake moderately \> liver) or 5 (uptake markedly \> liver and/or new lesions) with increased uptake from baseline; New fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology or in bone marrow; Individual node/lesion abnormal with longest diameter \> 1.5 cm, ≥ 50% increase from nadir; Splenic length increase \> 50% of prior increase beyond baseline or ≥ 2 cm increase if no prior splenomegaly; New/recurrent splenomegaly, progression of non-measurable lesions, new lesion, or new/recurrent bone marrow involvement. KM estimates was used for analysis.

    Time frame: From randomization date up to a median follow-up: 24.9 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per Blinded Central Assessment

    ORR: Percentage of participants with CR (Complete Metabolic Response (CMR);Complete Radiologic Response (CRR)) or PR (partial metabolic response (PMR); partial radiologic response (PRR)).CMR: Positron emission tomography (PET) 5-point scale scores: 1-No uptake above background; 2-Uptake ≤mediastinum; 3-Uptake \>mediastinum but ≤liver, with/without residual mass; no new lesions, no FDG-avid disease in bone marrow. CRR: Target nodes/nodal masses regressed ≤1.5 cm in longest diameter, no extralymphatic sites, no non-measured lesions, normal organ size, no new sites, normal bone marrow morphology. PMR: Scores 4 (uptake moderately \>liver), 5 (uptake markedly \>liver, new lesions) with reduced uptake from baseline and residual mass, no new lesions. Responding at interim/residual disease at end of treatment. PRR: ≥50% decrease in sum of diameters of up to 6 target measurable lesions, no increase in non-measured lesions, spleen length decreased \>50% if previously enlarged, no new lesion sites.

    Time frame: From randomization date up to a median follow-up: 24.9 months

  2. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death from any cause. Kaplan-Meier (KM) estimates were used for analysis.

    Time frame: Up to 74.9 months

  3. Duration of Response (DOR) Per Blinded Central Assessments

    DOR was defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and was the time from the first objective response per Lugano classification to disease progression or death from any cause. Objective response was defined in outcome measure 2 and disease progression was defined in outcome measure 1. KM estimates were used for analysis.

    Time frame: From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (Up to 37.8 months)

  4. Modified Event Free Survival (mEFS) Per Blinded Central Assessment

    Modified event free survival is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.

    Time frame: From randomization date up to a median follow-up: 24.9 months

  5. EFS Per Investigator Disease Assessments

    EFS was defined as the time from randomization to the earliest date of disease progression per the Lugano Classification, best response of stable disease (SD) up to and including Day 150, commencement of new lymphoma therapy, or death from any cause. Disease progression is defined in outcome measure 1.

    Time frame: From randomization date up to a median follow-up: 47.2 months

  6. Progression-Free Survival (PFS) Per Investigator Disease Assessments

    PFS is defined as the time from the randomization date to the date of disease progression per Lugano classification or death from any cause. Disease progression is defined in outcome measure 1. KM estimates were used for analysis.

    Time frame: From randomization date up to a median follow-up: 47.2 months

  7. Modified Event Free Survival (mEFS) Per Investigator Assessment

    mEFS is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.

    Time frame: From randomization date up to a median follow-up: 47.2 months

  8. Change From Baseline in Global Health Status Scores

    Global health status was measured using European Organization for Research and Treatment of Cancer (EORTC) Quality Life Questionnaire (QLQ) C-30. This health related quality of life (HRQoL) questionnaire was comprised of 15 questions on functional scales, 13 questions on symptom scales and 2 on global health status scale. Global Health Status used a 7 point Likert-type scale of 1 (Very poor) to 7 (Excellent). All scores were transformed to 0-100. Higher scores for Global Health Status indicated better HRQoL.

    Time frame: Baseline, Days 50, 100, and 150; Months 9, 12, 15, 18, 21 and 24

  9. Change From Baseline in EORTC QLQ-C30 Physical Functioning Score

    The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The Physical Functioning domain includes 5 questions in which participants were asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 7 (excellent). The 5 scores were transformed to a scale from 0 to 100, where a high score indicated better QoL. A positive change from baseline indicates better QoL.

    Time frame: Baseline, Days 50, 100, 150, Months 9, 12, 15, 18, 21 and 24

  10. Changes From Baseline in the European Quality of Life Five Dimensions Five Levels Scale Index Score

    The Euro-QOL (EQ) Five Dimensions (5D) Five Levels (5L), EQ-5D-5L questionnaire was a generic measure of health status that provided a simple descriptive profile and a single index value. The EQ-5D-5L comprised 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health stated using a visual analog scale (VAS). The total score for EQ-5D-5L index was presented on a range from 0 to 1 where higher scores indicated better outcome. A positive change from Baseline indicates improvement.

    Time frame: Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24

  11. Change From Baseline in EQ-5D-5L VAS Scale Score

    The EQ-5D-5L VAS is a 20-cm VAS for recording self-rated current HRQoL state and is used to describe the participants' health status on the day of the assessment. The EQ-5D-5L VAS score is recorded by each participant for his or her current HRQoL state and scored 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"). The value 100 indicates improvement.

    Time frame: Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24

  12. Number of Participants With Post-dose Anti-Axicabtagene Ciloleucel Antibodies

    Time frame: Up to 74.9 months

  13. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any AE that begins on or after the first dose of study treatment (axicabtagene ciloleucel infusion or SOC), excluding bridging therapy.

    Time frame: From first dose up to 61.8 months

  14. Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher

    Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.

    Time frame: From first dose up to 61.8 months

  15. Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher

    Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.

    Time frame: From first dose up to 61.8 months

07

Results

Posted Mar 7, 2024

Participant flow

Participants were enrolled at study sites in North America, Middle East, Europe, and Australia.

Participant flow — Overall Study
MilestoneAxicabtagene CiloleucelStandard of Care Therapy
Started180179
Completed267
Not completed178112
Withdrew: Death8491
Withdrew: Rollover to long-term follow-up study criteria800
Withdrew: Subject withdrawal of consent from further follow-up313
Withdrew: Lost to follow-up95
Withdrew: Reason not specified22
Withdrew: Investigator decision01

Outcome measures

PrimaryEvent Free Survival (EFS) Per Blinded Central Assessment

EFS:Time from randomization to disease progression (PD), best response of stable disease (SD) up to Day 150, start of new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD=Score 4 (uptake moderately \> liver) or 5 (uptake markedly \> liver and/or new lesions) with increased uptake from baseline; New fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology or in bone marrow; Individual node/lesion abnormal with longest diameter \> 1.5 cm, ≥ 50% increase from nadir; Splenic length increase \> 50% of prior increase beyond baseline or ≥ 2 cm increase if no prior splenomegaly; New/recurrent splenomegaly, progression of non-measurable lesions, new lesion, or new/recurrent bone marrow involvement. KM estimates was used for analysis.

Time frame:
From randomization date up to a median follow-up: 24.9 months
Reported as:
Median · months
Event Free Survival (EFS) Per Blinded Central Assessment
monthsAxicabtagene CiloleucelStandard of Care Therapy
Event Free Survival (EFS) Per Blinded Central Assessment8.3 (4.5 to 15.8)2.0 (1.6 to 2.8)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Log Rank · p = <0.0001 (Stratified (randomization factors) log-rank p-value.) · Hazard ratio (hr): 0.398 · 95% CI 0.308 to 0.514Hazard ratio (95% confidence interval (CI)), stratified using randomization stratification factors.
SecondaryObjective Response Rate (ORR) Per Blinded Central Assessment

ORR: Percentage of participants with CR (Complete Metabolic Response (CMR);Complete Radiologic Response (CRR)) or PR (partial metabolic response (PMR); partial radiologic response (PRR)).CMR: Positron emission tomography (PET) 5-point scale scores: 1-No uptake above background; 2-Uptake ≤mediastinum; 3-Uptake \>mediastinum but ≤liver, with/without residual mass; no new lesions, no FDG-avid disease in bone marrow. CRR: Target nodes/nodal masses regressed ≤1.5 cm in longest diameter, no extralymphatic sites, no non-measured lesions, normal organ size, no new sites, normal bone marrow morphology. PMR: Scores 4 (uptake moderately \>liver), 5 (uptake markedly \>liver, new lesions) with reduced uptake from baseline and residual mass, no new lesions. Responding at interim/residual disease at end of treatment. PRR: ≥50% decrease in sum of diameters of up to 6 target measurable lesions, no increase in non-measured lesions, spleen length decreased \>50% if previously enlarged, no new lesion sites.

Time frame:
From randomization date up to a median follow-up: 24.9 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per Blinded Central Assessment
percentage of participantsAxicabtagene CiloleucelStandard of Care Therapy
Objective Response Rate (ORR) Per Blinded Central Assessment83 (77.1 to 88.5)50 (42.7 to 57.8)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified (randomization factor) CMH test p-value.) · Difference in orr: 33.1 · 95% CI 23.2 to 42.195% CI for the difference in ORR was from Wilson's score method with continuity correction.
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization to death from any cause. Kaplan-Meier (KM) estimates were used for analysis.

Time frame:
Up to 74.9 months
Reported as:
Median · months
Overall Survival (OS)
monthsAxicabtagene CiloleucelStandard of Care Therapy
Overall Survival (OS)NA (28.3 to NA)35.1 (18.5 to NA)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Log Rank · p = 0.027 (Stratified log-rank (randomization factor) p-value.) · Hazard ratio (hr): 0.730 · 95% CI 0.530 to 1.007Stratified Cox regression models were used to estimate hazard ratio and 2-sided CIs for axicabtagene ciloleucel relative to standard of care therapy. The Breslow method was used to handle the ties for the Cox regression models.
SecondaryDuration of Response (DOR) Per Blinded Central Assessments

DOR was defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and was the time from the first objective response per Lugano classification to disease progression or death from any cause. Objective response was defined in outcome measure 2 and disease progression was defined in outcome measure 1. KM estimates were used for analysis.

Time frame:
From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (Up to 37.8 months)
Reported as:
Median · months
Duration of Response (DOR) Per Blinded Central Assessments
monthsAxicabtagene CiloleucelStandard of Care Therapy
Duration of Response (DOR) Per Blinded Central Assessments26.9 (13.6 to NA)8.9 (5.7 to NA)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Log Rank · p = 0.0695 (Stratified (randomization stratification factors) log-rank test.) · Hazard ratio (hr): 0.736 · 95% CI 0.488 to 1.108Stratified Cox regression models were used to estimate hazard ratio and 2-sided 95% CIs for axicabtagene ciloleucel relative to standard of care.
SecondaryModified Event Free Survival (mEFS) Per Blinded Central Assessment

Modified event free survival is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.

Time frame:
From randomization date up to a median follow-up: 24.9 months
Reported as:
Median · months
Modified Event Free Survival (mEFS) Per Blinded Central Assessment
monthsAxicabtagene CiloleucelStandard of Care Therapy
Modified Event Free Survival (mEFS) Per Blinded Central Assessment10.3 (5.0 to 21.5)2.0 (1.6 to 2.8)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by response to first-line therapy and second-line age-adjusted IPI as data collected on case report forms.) · Hazard ratio (hr): 0.376 · 95% CI 0.290 to 0.487Stratified Cox regression models were used to estimate hazard ratio and 2-sided 95% CIs for axicabtagene ciloleucel relative to standard of care therapy. The Breslow method was used to handle the ties for the Cox regression models.
SecondaryEFS Per Investigator Disease Assessments

EFS was defined as the time from randomization to the earliest date of disease progression per the Lugano Classification, best response of stable disease (SD) up to and including Day 150, commencement of new lymphoma therapy, or death from any cause. Disease progression is defined in outcome measure 1.

Time frame:
From randomization date up to a median follow-up: 47.2 months
Reported as:
Median · months
EFS Per Investigator Disease Assessments
monthsAxicabtagene CiloleucelStandard of Care Therapy
EFS Per Investigator Disease Assessments10.8 (5.0 to 25.5)2.3 (1.7 to 3.1)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Hazard ratio (hr): 0.422 · 95% CI 0.327 to 0.545Stratified Cox regression models were used to estimate hazard ratio and 2-sided 95% CIs for axicabtagene ciloleucel relative to standard of care therapy. The Breslow method was used to handle the ties for the Cox regression models.
SecondaryProgression-Free Survival (PFS) Per Investigator Disease Assessments

PFS is defined as the time from the randomization date to the date of disease progression per Lugano classification or death from any cause. Disease progression is defined in outcome measure 1. KM estimates were used for analysis.

Time frame:
From randomization date up to a median follow-up: 47.2 months
Reported as:
Median · months
Progression-Free Survival (PFS) Per Investigator Disease Assessments
monthsAxicabtagene CiloleucelStandard of Care Therapy
Progression-Free Survival (PFS) Per Investigator Disease Assessments14.7 (5.4 to 43.5)3.7 (2.9 to 5.3)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Hazard ratio (hr): 0.506 · 95% CI 0.383 to 0.669Stratified Cox regression models were used to estimate hazard ratio and 2-sided 95% CIs for axicabtagene ciloleucel relative to standard of care therapy. The Breslow method was used to handle the ties for the Cox regression models.
SecondaryModified Event Free Survival (mEFS) Per Investigator Assessment

mEFS is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.

Time frame:
From randomization date up to a median follow-up: 47.2 months
Reported as:
Median · months
Modified Event Free Survival (mEFS) Per Investigator Assessment
monthsAxicabtagene CiloleucelStandard of Care Therapy
Modified Event Free Survival (mEFS) Per Investigator Assessment12.6 (5.0 to 29.1)2.3 (1.7 to 3.1)
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Hazard ratio (hr): 0.412 · 95% CI 0.318 to 0.532Stratified Cox regression models were used to estimate hazard ratio and 2-sided 95% CIs for axicabtagene ciloleucel relative to standard of care therapy. The Breslow method was used to handle the ties for the Cox regression models.
SecondaryChange From Baseline in Global Health Status Scores

Global health status was measured using European Organization for Research and Treatment of Cancer (EORTC) Quality Life Questionnaire (QLQ) C-30. This health related quality of life (HRQoL) questionnaire was comprised of 15 questions on functional scales, 13 questions on symptom scales and 2 on global health status scale. Global Health Status used a 7 point Likert-type scale of 1 (Very poor) to 7 (Excellent). All scores were transformed to 0-100. Higher scores for Global Health Status indicated better HRQoL.

Time frame:
Baseline, Days 50, 100, and 150; Months 9, 12, 15, 18, 21 and 24
Reported as:
Mean · Score on scale
Change From Baseline in Global Health Status Scores
Score on scaleAxicabtagene CiloleucelStandard of Care Therapy
Score at Baseline68.6 ± 19.970.1 ± 23.1
Change from Baseline at Study Day 50-7.4 ± 20.2-8.5 ± 22.7
Change from Baseline at Study Day 1001.3 ± 19.6-15.3 ± 22.7
Change from Baseline at Study Day 1505.9 ± 24.9-4.2 ± 23.7
Change from Baseline at Study Month 98.0 ± 22.73.5 ± 23.7
Change from Baseline at Study Month 128.6 ± 24.99.1 ± 20.2
Change from Baseline at Study Month 159.0 ± 22.39.9 ± 18.9
Change from Baseline at Study Month 1810.2 ± 20.96.5 ± 21.3
Change from Baseline at Study Month 2110.0 ± 21.515.0 ± 19.6
Change from Baseline at Study Month 248.6 ± 21.013.2 ± 17.2
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = <0.0001 (False Discovery Rate Methodology) · Mixed model with repeated measures: 18.1 · 95% CI 12.3 to 23.9
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.0124 (False Discovery Rate Methodology) · Mixed model with repeated measures: 9.8 · 95% CI 2.6 to 17.0
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.2655 (False Discovery Rate Methodology) · Mixed model with repeated measures: 4.4 · 95% CI -3.3 to 12.0
SecondaryChange From Baseline in EORTC QLQ-C30 Physical Functioning Score

The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The Physical Functioning domain includes 5 questions in which participants were asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 7 (excellent). The 5 scores were transformed to a scale from 0 to 100, where a high score indicated better QoL. A positive change from baseline indicates better QoL.

Time frame:
Baseline, Days 50, 100, 150, Months 9, 12, 15, 18, 21 and 24
Reported as:
Mean · Score on scale
Change From Baseline in EORTC QLQ-C30 Physical Functioning Score
Score on scaleAxicabtagene CiloleucelStandard of Care Therapy
Score at Baseline83.5 ± 17.785.3 ± 18.9
Change from Baseline at Study Day 50-12.9 ± 21.7-8.3 ± 17.5
Change from Baseline at Study Day 100-1.8 ± 17.8-15.0 ± 19.1
Change from Baseline at Study Day 1501.3 ± 18.9-5.2 ± 21.3
Change from Baseline at Study Month 94.1 ± 17.1-2.4 ± 23.5
Change from Baseline at Study Month 123.4 ± 20.80.4 ± 20.3
Change from Baseline at Study Month 153.9 ± 19.31.6 ± 16.1
Change from Baseline at Study Month 185.0 ± 15.13.2 ± 17.9
Change from Baseline at Study Month 216.0 ± 16.14.3 ± 21.4
Change from Baseline at Study Month 243.7 ± 16.55.6 ± 8.0
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = <0.0001 (False Discovery Rate Methodology.) · Mixed model with repeated measures: 13.1 · 95% CI 8.0 to 18.2
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.1253 (False Discovery Rate Methodology.) · Mixed model with repeated measures: 5.1 · 95% CI -0.9 to 11.0
SecondaryChanges From Baseline in the European Quality of Life Five Dimensions Five Levels Scale Index Score

The Euro-QOL (EQ) Five Dimensions (5D) Five Levels (5L), EQ-5D-5L questionnaire was a generic measure of health status that provided a simple descriptive profile and a single index value. The EQ-5D-5L comprised 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health stated using a visual analog scale (VAS). The total score for EQ-5D-5L index was presented on a range from 0 to 1 where higher scores indicated better outcome. A positive change from Baseline indicates improvement.

Time frame:
Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24
Reported as:
Mean · Score on scale
Changes From Baseline in the European Quality of Life Five Dimensions Five Levels Scale Index Score
Score on scaleAxicabtagene CiloleucelStandard of Care Therapy
Score at Baseline0.803 ± 0.2100.799 ± 0.250
Change from Baseline at Study Day 50-0.049 ± 0.205-0.003 ± 0.198
Change from Baseline at Study Day 1000.012 ± 0.191-0.068 ± 0.246
Change from Baseline at Study Day 1500.050 ± 0.2120.014 ± 0.208
Change from Baseline at Study Month 90.064 ± 0.1900.015 ± 0.197
Change from Baseline at Study Month 120.072 ± 0.2410.051 ± 0.200
Change from Baseline at Study Month 150.051 ± 0.2090.080 ± 0.125
Change from Baseline at Study Month 180.094 ± 0.1800.072 ± 0.188
Change from Baseline at Study Month 210.089 ± 0.2350.110 ± 0.177
Change from Baseline at Study Month 240.051 ± 0.2390.117 ± 0.138
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.0112 (False Discovery Rate Methodology.) · Mixed model with repeated measures: 0.081 · 95% CI 0.024 to 0.138
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.3703 (False Discovery Rate Methodology.) · Mixed model with repeated measures: 0.028 · 95% CI -0.034 to 0.091
SecondaryChange From Baseline in EQ-5D-5L VAS Scale Score

The EQ-5D-5L VAS is a 20-cm VAS for recording self-rated current HRQoL state and is used to describe the participants' health status on the day of the assessment. The EQ-5D-5L VAS score is recorded by each participant for his or her current HRQoL state and scored 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"). The value 100 indicates improvement.

Time frame:
Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24
Reported as:
Mean · Score on scale
Change From Baseline in EQ-5D-5L VAS Scale Score
Score on scaleAxicabtagene CiloleucelStandard of Care Therapy
Score at Baseline72.4 ± 18.774.4 ± 20.1
Change from Baseline at Study Day 50-1.9 ± 18.7-4.4 ± 16.7
Change from Baseline at Study Day 1004.0 ± 18.4-8.2 ± 19.8
Change from Baseline at Study Day 1509.1 ± 19.4-2.2 ± 22.2
Change from Baseline at Study Month 911.4 ± 19.94.4 ± 19.0
Change from Baseline at Study Month 1210.1 ± 19.96.6 ± 17.8
Change from Baseline at Study Month 1510.7 ± 20.78.2 ± 13.7
Change from Baseline at Study Month 1815.1 ± 17.19.3 ± 13.6
Change from Baseline at Study Month 2114.0 ± 17.210.1 ± 14.3
Change from Baseline at Study Month 2410.9 ± 18.812.2 ± 15.3
Statistical analysis
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = <0.0001 (False Discovery Rate Methodology) · Mixed model with repeated measures: 13.7 · 95% CI 8.5 to 18.8Mixed Model with Repeated Measures Differences in Change from Baseline.
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.0004 (False Discovery Rate Methodology) · Mixed model with repeated measures: 11.3 · 95% CI 5.4 to 17.1
  • Axicabtagene Ciloleucel vs Standard of Care Therapy · Mixed Model with Repeated Measures · p = 0.2549 (False Discovery Rate Methodology.) · Mixed model with repeated measures: 3.8 · 95% CI -2.3 to 10.0Mixed Model with Repeated Measures Differences in Change from Baseline.
SecondaryNumber of Participants With Post-dose Anti-Axicabtagene Ciloleucel Antibodies
Time frame:
Up to 74.9 months
Reported as:
Count of participants · Participants
Number of Participants With Post-dose Anti-Axicabtagene Ciloleucel Antibodies
ParticipantsAxicabtagene Ciloleucel
Number of Participants With Post-dose Anti-Axicabtagene Ciloleucel Antibodies0
SecondaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any AE that begins on or after the first dose of study treatment (axicabtagene ciloleucel infusion or SOC), excluding bridging therapy.

Time frame:
From first dose up to 61.8 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
percentage of participantsAxicabtagene CiloleucelStandard of Care Therapy
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)100.0100.0
SecondaryPercentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher

Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.

Time frame:
From first dose up to 61.8 months
Reported as:
Number · percentage of participants
Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher
percentage of participantsAxicabtagene CiloleucelStandard of Care Therapy
Hemoglobin (mmol/L)00
Leukocytes (10^9/L)01
Lymphocytes (10^9/L)00
Alanine Aminotransferase (U/L)64
Alkaline Phosphatase (U/L)11
Aspartate Aminotransferase (U/L)62
Bilirubin (umol/L)21
Calcium (mmol/L)21
Creatinine (umol/L)41
Glucose (mmol/L)145
Magnesium (mmol/L)20
Potassium (mmol/L)01
Sodium (mmol/L)00
SecondaryPercentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher

Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening. Percentages were rounded off.

Time frame:
From first dose up to 61.8 months
Reported as:
Number · percentage of participants
Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher
percentage of participantsAxicabtagene CiloleucelStandard of Care Therapy
Hemoglobin (mmol/L)4144
Leukocytes (10^9/L)9556
Lymphocytes (10^9/L)9968
Neutrophils (10^9/L)9451
Platelets (10^9/L)2663
Albumin (g/L)41
Calcium (mmol/L)82
Glucose (mmol/L)00
Magnesium (mmol/L)23
Phosphate (mmol/L)55
Potassium (mmol/L)67
Sodium (mmol/L)122

Adverse events

Collected over All-cause mortality and Adverse events: Up to 74.9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axicabtagene Ciloleucel Treatment81/180 (45%)96/170 (56.5%)170/170 (100%)
Standard of Care Therapy101/179 (56.4%)78/168 (46.4%)166/168 (98.8%)
Retreatment Axicabtagene Ciloleucel3/10 (30%)2/10 (20%)10/10 (100%)
Most frequent serious events
Showing 10 of 167
Most frequent serious events
EventAxicabtagene Ciloleucel TreatmentStandard of Care TherapyRetreatment Axicabtagene Ciloleucel
PyrexiaGeneral disorders27/1708/1680/10
Febrile neutropeniaBlood and lymphatic system disorders6/17022/1680/10
FuruncleInfections and infestations0/1700/1681/10
Urinary tract infectionInfections and infestations3/1700/1681/10
Neutrophil count decreasedInvestigations3/1703/1681/10
EncephalopathyNervous system disorders17/1701/1680/10
HypotensionVascular disorders15/1703/1681/10
PneumoniaInfections and infestations16/1704/1680/10
AphasiaNervous system disorders9/1700/1680/10
Acute kidney injuryRenal and urinary disorders4/1708/1680/10
Most frequent other events
Showing 10 of 94
Most frequent other events
EventAxicabtagene Ciloleucel TreatmentStandard of Care TherapyRetreatment Axicabtagene Ciloleucel
PyrexiaGeneral disorders149/17040/1689/10
NauseaGastrointestinal disorders68/170116/1684/10
HeadacheNervous system disorders69/17043/1686/10
AnaemiaBlood and lymphatic system disorders71/17090/1684/10
FatigueGeneral disorders69/17087/1682/10
Neutrophil count decreasedInvestigations51/17045/1685/10
NeutropeniaBlood and lymphatic system disorders75/17028/1682/10
DiarrhoeaGastrointestinal disorders71/17066/1682/10
Sinus tachycardiaCardiac disorders58/17016/1684/10
White blood cell count decreasedInvestigations46/17037/1684/10

Baseline characteristics

The Full Analysis Set (FAS) consisted of all randomized participants.

Age, Categorical
Age, Categorical(Participants)Axicabtagene CiloleucelStandard of Care TherapyTotal
<=18 years000
Between 18 and 65 years129121250
>=65 years5158109
Age, Continuous
Age, Continuous(years)Axicabtagene CiloleucelStandard of Care TherapyTotal
Mean57.1 ± 12.057.4 ± 12.257.2 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Axicabtagene CiloleucelStandard of Care TherapyTotal
Female7052122
Male110127237
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Axicabtagene CiloleucelStandard of Care TherapyTotal
Hispanic or Latino10818
Not Hispanic or Latino167169336
Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Axicabtagene CiloleucelStandard of Care TherapyTotal
American Indian or Alaska Native011
Asian121022
Native Hawaiian or Other Pacific Islander213
Black or African American11718
White145152297
More than one race10818
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Axicabtagene CiloleucelStandard of Care TherapyTotal
United States130120250
United Kingdom4812
Switzerland101
Spain6915
Canada101020
Belgium437
Netherlands111425
Sweden011
Italy213
Israel426
Australia224
France426
Germany156
Austria123
08

Study locations

72 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • UCLA
    Santa Monica, California 90404, United States
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Moffitt Cancer Center
    Tampa, Florida 12902, United States
  • Northwestern University
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Iowa Hospitals and Clinincs
    Iowa City, Iowa 52242, United States
  • The University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
  • University of Maryland, Greenbaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic, Patient Location
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St Louis, Missouri 63130, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Henry-Joyce Cancer Center
    Nashville, Tennessee 37232, United States
  • The University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Peter MacCallum Cancer Center
    Melbourne, Victoria 3000, Australia
  • Universitatsklinikum Graz, Division of Hematology
    Graz, 6020, Austria
  • Medizinische Universitat Innsbruck, Innere Medizin V - Hamatologie und Onkologie
    Innsbruck, 6020, Austria
  • Cliniques Universiaires Saint-Luc
    Brussels, Belgium
  • UZ Gasthuisberg
    Leuven, Belgium
  • Vancouver General Hospital
    Vancouver, British Columbia, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Uninversity Health Network - Princess Margaret Cancer Center
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Center
    Montreal, Quebec H4A 3J1, Canada
  • QEII Health Sciences Centre
    Halifax, B3H 2Y9, Canada
  • Centre Integre Universitaire de Sante et Services Sociaux de l'Est-de-l'lle-de-Montreal / Hopital Maisonneuve-Rosemont
    Montreal, H1T 2M4, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, K1H 8L6, Canada
  • CHU de Quebec-Universite Laval, Hopital de L'Enfante-Jesus
    Québec, G1J 1Z4, Canada
  • CHRU de Lille - Hopital Claude Huriez
    Lille, 59037, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • Centre Hospitalier Lyon-Sud - Service d'Hematologie clinique
    Pierre-Bénite, 69495, France
  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
    Rennes, 35033, France
  • Universitäts-klinikum Dresden
    Dresden, 01307, Germany
  • Universitatsmedizin Gottingen
    Göttingen, 37075, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitäts-klinikum Würzburg
    Würzburg, 97080, Germany
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Instituto di Ematologia "L. e A. Seragnoli" - Dipartimento di Medicina Specialistica Diagnostica e Sperimentale
    Bologna, 40138, Italy
  • IRCCS Ospedale San Raffaele di Milano
    Milan, 20132, Italy
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • University Medical Center Groningen
    Groningen, 9700 RB, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3011PL, Netherlands
  • University Medical Center Utrecht
    Utrecht, Netherlands
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Institut Catala d'Oncologia
    Barcelona, 08908, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Uppsala Akademiska Sjukhus
    Uppsala, 75185, Sweden
  • IOSI, OSpedale Regionale Bellinzona e Valli
    Bellinzona, 6500, Switzerland
  • University Hospital Zurich
    Zurich, 8091, Switzerland
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2GW, United Kingdom
  • Barts Health NHS Trust
    London, EC1A 7BE, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, NW3 2QG, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. PubMed 25113753 ↗
  • Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15. PubMed 26980727 ↗
  • Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C, Kersten MJ. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022 Nov 24;140(21):2248-2260. doi: 10.1182/blood.2022015478. PubMed 35839452 ↗
  • Kersten MJ, Qiao Y, Shah R, Solem C, Snider JT, To C, Cheng P, Spooner C, Perales MA. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma. Transplant Cell Ther. 2023 May;29(5):335.e1-335.e8. doi: 10.1016/j.jtct.2023.01.008. Epub 2023 Jan 14. PubMed 36646322 ↗
  • Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. PubMed 34891224 ↗
  • Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res. 2023 May 15;29(10):1894-1905. doi: 10.1158/1078-0432.CCR-22-3136. PubMed 36999993 ↗
  • Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. PubMed 37272527 ↗
  • Filosto S, Vardhanabhuti S, Canales M, Poiré X, Lekakis LJ, de Vos S, et al. Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma. Cancer Res. 2022;82(12_Supplement):CT004.
  • Ghobadi A, Munoz J, Westin J, Locke FL, Miklos DB, Rapoport AP, et al. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study. Blood. 2022;140(Supplement 1):1595-1597.
  • Locke FL, Oluwole OO, Kuruvilla J, Thieblemont C, Morschhauser F, Salles G, et al. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7. Blood. 2022;140(Supplement 1):638-640.
  • Chartier M, Filosto S, Peyret T, Chiney M, Milletti F, Budka J, Ndi A, Dong J, Vardhanabhuti S, Mao D, Duffull S, Dodds M, Shen R. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma. Clin Pharmacokinet. 2024 Sep;63(9):1283-1299. doi: 10.1007/s40262-024-01413-z. Epub 2024 Sep 6. PubMed 39240498 ↗
  • Filosto S, Vardhanabhuti S, Canales MA, Poire X, Lekakis LJ, de Vos S, Portell CA, Wang Z, To C, Schupp M, Poddar S, Trinh T, Warren CM, Aguilar EG, Budka J, Cheng P, Chou J, Bot A, Shen RR, Westin JR. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discov. 2024 Jan 8;5(1):21-33. doi: 10.1158/2643-3230.BCD-23-0112. PubMed 37983485 ↗
  • Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk J, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Adv. 2024 Jun 11;8(11):2982-2990. doi: 10.1182/bloodadvances.2023011532. PubMed 38315832 ↗
  • Locke FL, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, et al. Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). J Clin Oncol.2022;40(16_suppl):7565
  • Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, Lee C, Zinzani PL, Kroger N, Lopez-Guillermo A, Greinix H, Zhang W, Tiwari G, Budka J, Marincola FM, To C, Mattie M, Schupp M, Cheng P, Bot A, Shen R, Bedognetti D, Miao H, Galon J. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024 Feb;30(2):507-518. doi: 10.1038/s41591-023-02754-1. Epub 2024 Jan 17. PubMed 38233586 ↗
  • Locke FL, Oluwole OO, Kuruvilla J, Thieblemont C, Morschhauser F, Salles G, Rowe SP, Vardhanabhuti S, Winters J, Filosto S, To C, Cheng P, Schupp M, Korn R, Kersten MJ. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood. 2024 Jun 13;143(24):2464-2473. doi: 10.1182/blood.2023021620. PubMed 38557775 ↗
  • Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May;99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024 Mar 19. PubMed 38504387 ↗
  • Tian Y, Budka J, Locke FL, Westin JR, To C, Tiwari G, Mao D, Bedognetti D, Shen RR, Andrade J, Filosto S. Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). Front Oncol. 2025 Feb 27;15:1519473. doi: 10.3389/fonc.2025.1519473. eCollection 2025. PubMed 40083872 ↗
  • Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 Jun 27;143(26):2722-2734. doi: 10.1182/blood.2023023447. PubMed 38635762 ↗
  • The Lancet Haematology. The role of conferences in tackling inequalities. Lancet Haematol. 2022 Feb;9(2):e81. doi: 10.1016/S2352-3026(22)00008-4. No abstract available. PubMed 35114155 ↗
  • Del Pozo Martin Y. 2021 ASH annual meeting. Lancet Haematol. 2022 Feb;9(2):e92-e93. doi: 10.1016/S2352-3026(21)00384-7. Epub 2021 Dec 16. No abstract available. PubMed 34922648 ↗
  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗
  • Thiruvengadam SK, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11. PubMed 33288485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Mar 2021, 37 months.

Results were first posted in Mar 2024, 2 years 11 months after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 37 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2017
First posted
Jan 5, 2018
StartActual
Jan 25, 2018
Primary completionActual
Mar 18, 2021
CompletionActual
Nov 25, 2024
Results first posted
Mar 7, 2024
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03391466
Responsible party
Sponsor
First posted
Jan 5, 2018
Start date
Jan 25, 2018
Primary completion
Mar 18, 2021
Completion
Nov 25, 2024
Results posted
Mar 7, 2024
Last update
Dec 1, 2025

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axicabtagene ciloleucel

Start the discussion